Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis.

Karolina Strzebonska Mateusz T Wasylewski Lucja Zaborowska Maciej Polak Emilia Slugocka Jakub Stras Mateusz Blukacz Bishal Gyawali Marcin Waligora

Published in: Targeted oncology (2021)

We provide an estimate for the risks and benefits of participation in pediatric phase II cancer trials. These data may be used as an empirical basis for informed communication about benefits and burdens in pediatric oncology research.

Keyphrases

phase ii
clinical trial
open label
palliative care
phase iii
double blind
placebo controlled
papillary thyroid
physical activity
squamous cell carcinoma
randomized controlled trial
risk assessment
electronic health record
big data
climate change
artificial intelligence